Ad­ynxx drug failed in PhII but it’s go­ing in­to PhI­II any­way; Deer­field leads $50M raise for Sol­lis

→ San Fran­cis­co-based Ad­ynxx says that their Phase II study for a new non-opi­oid pain drug failed — but they’re go­ing in­to Phase III in any case. In­ves­ti­ga­tors hunt­ed up pa­tients based on the Pain Cat­a­stro­phiz­ing Scale, fail­ing to see a sta­tis­ti­cal ben­e­fit in the post-sur­gi­cal group for briv­o­ligide (AYX1) over a place­bo. They re­cruit­ed 210 pa­tients. The biotech, how­ev­er, did find the re­sults it was look­ing for in a group of pa­tients with high PCS num­bers, and that’s where they’ll be fo­cus­ing in Phase III. That strat­e­gy of push­ing in­to Phase III af­ter a failed Phase II has proven to be a par­tic­u­lar­ly risky ap­proach to drug de­vel­op­ment, but that isn’t stop­ping Ad­ynxx.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER